MARKET

RGLS

RGLS

Regulus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8800
+0.0600
+7.32%
After Hours: 0.9200 +0.04 +4.55% 19:57 05/14 EDT
OPEN
0.8421
PREV CLOSE
0.8200
HIGH
0.9200
LOW
0.8360
VOLUME
1.39M
TURNOVER
--
52 WEEK HIGH
2.320
52 WEEK LOW
0.4222
MARKET CAP
65.93M
P/E (TTM)
-1.6076
1D
5D
1M
3M
1Y
5Y
Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit
, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that , President and Chief Executive Officer of Regulus, will present at the O...
PR Newswire - PRF · 1d ago
--Wedbush Halves Regulus Therapeutics' PT to $1 From $2 on RGLD4326 Timeline for Autosomal Dominant Polycystic Kidney Disease; Neutral Rating Kept
MT Newswires · 1d ago
--HC Wainwright Adjusts Regulus Therapeutics' Price Target to $2 From $1.50, Maintains Buy Rating
MT Newswires · 1d ago
HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $2
HC Wainwright & Co. maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and raises the price target from $1.5 to $2.
Benzinga · 1d ago
BRIEF-Regulus Therapeutics Reports Q1 Loss Per Share $0.08
reuters.com · 2d ago
Regulus Therapeutics Q1 EPS $(0.08) Beats $(0.09) Estimate
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 68 percent increase over losses of $(0.25) per share from
Benzinga · 2d ago
Regulus Therapeutics EPS beats by $0.01
Regulus Therapeutics (RGLS): Q1 GAAP EPS of -$0.08 beats by $0.01.As of March 31, 2021, Regulus had $31.6 million in cash and cash equivalents.Press Release
Seekingalpha · 2d ago
Regulus Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Regulus Therapeutics, Inc. (NASDAQ:RGLS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 5:00 PM Eastern Time.
ACCESSWIRE · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGLS. Analyze the recent business situations of Regulus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGLS stock price target is 1.250 with a high estimate of 2.000 and a low estimate of 0.5000.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 26.57M
% Owned: 35.47%
Shares Outstanding: 74.92M
TypeInstitutionsShares
Increased
7
4.97M
New
11
2.64M
Decreased
3
48.07K
Sold Out
5
467.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Independent Director
Stelios Papadopoulos
President/Chief Executive Officer/Director
Joseph Hagan
Chief Financial Officer
Crispina Calsada
Senior Vice President/General Counsel
Christopher Aker
Chief Scientific Officer
Denis Drygin
Director
Alice Huang
Independent Director
David Baltimore
Independent Director
Kathryn Collier
Independent Director
Jake Nunn
Independent Director
William Rastetter
Independent Director
Hugh Rosen
Independent Director
Simos Simeonidis
Independent Director
Pascale Witz
No Data
  • All
  • Financials
  • Insiders
More
About RGLS
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.